Package Leaflet: Information for the User
Yuvanci 10 mg/20 mg film-coated tablets
Yuvanci 10 mg/40 mg film-coated tablets
macitentan/tadalafil
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Yuvanci contains two active substances: macitentan and tadalafil. Macitentan belongs to a class of medicines called endothelin receptor antagonists (ERAs). Tadalafil belongs to a class of medicines called phosphodiesterase type 5 inhibitors (PDE5i).
Yuvanci is used in adults for the long-term treatment of pulmonary arterial hypertension (PAH) of WHO Functional Class II or III. It is used as an alternative to taking macitentan and tadalafil as separate tablets.
PAH is high blood pressure in the blood vessels that carry blood from the heart to the lungs (pulmonary arteries). In people with PAH, these arteries become narrowed, so the heart has to work harder to pump blood through them. As a result, patients feel tired, dizzy, and have difficulty breathing. The class reflects the severity of the disease: patients with PAH of WHO Functional Class II have mild limitation of physical activity, while those with Class III have marked limitation of physical activity.
Yuvanci widens the pulmonary arteries, making it easier for the heart to pump blood through them. This reduces blood pressure, alleviates symptoms, increases the ability to perform physical activity, and improves the course of the disease.
Do not take Yuvanci if:
If you meet any of the above points, please tell your doctor.
Warnings and precautions
You will need blood tests before using Yuvanci and during treatment, as indicated by your doctor:
If you are a woman of childbearing age, your doctor will ask you to have a pregnancy test before starting Yuvanci and periodically (once a month) during treatment. See section 2 "Pregnancy and breast-feeding".
Your doctor will take blood to determine:
Yuvanci may cause increases in liver enzymes (proteins), which may be a sign that your liver is not working properly. Other signs that your liver may not be working properly are the following symptoms:
If you experience any of these signs during treatment with Yuvanci, tell your doctor immediately.
Yuvanci may cause anemia (low red blood cell count). If you experience any of the following symptoms, which may be symptoms of anemia, tell your doctor:
Consult your doctor before starting to take the tablets if
If you have kidney problems, talk to your doctor before using Yuvanci. During treatment with Yuvanci, there may be a higher risk of low blood pressure and anemia.
The use of medicines for the treatment of PAH, including Yuvanci, in patients with pulmonary veno-occlusive disease (obstruction of the pulmonary veins) may cause pulmonary edema (fluid accumulation in the lungs). Tell your doctor immediatelyif you experience signs of pulmonary edema during treatment with Yuvanci, such as:
Before taking Yuvanci, tell your doctorif you have any penile deformation, such as:
If you experience an erection that lasts 4 hours or more during treatment with Yuvanci, go to your doctor immediately.
Visual disturbances and sudden loss of vision have occurred with the use of tadalafil and PDE5 inhibitors. If you experience a reduction or sudden loss of vision or your vision is distorted or diminished during treatment, stop taking Yuvanci and contact your doctor immediately.
In some patients treated with tadalafil, a decrease or sudden loss of hearing has been observed. Although it is not known if the event is directly related to tadalafil, if you experience a decrease or sudden loss of hearing, contact your doctor immediately.
Children and adolescents
Do not give this medicine to children and adolescents under 18 years of age, as Yuvanci has not been tested in children.
Other medicines and Yuvanci
Tell your doctoror pharmacist if you are taking, have recently taken, or might take any other medicines.
Do not take Yuvanci if you are taking any of the following medicines:
Tell your doctor or pharmacist if you are taking any of the following medicines:
Medicines that may decrease the effectiveness of Yuvanci by decreasing the amount of Yuvanci in the blood, including:
Medicines that may increase the risk of side effects of Yuvanci, including:
Yuvanci with food and alcohol
If you are taking piperine as a dietary supplement, this may alter the way your body responds to some medicines like Yuvanci. Talk to your doctor or pharmacist if this is the case.
Drinking alcohol may temporarily lower blood pressure. If you have taken or are going to take Yuvanci, avoid excessive alcohol consumption (more than 5 units of alcohol), as this may increase the risk of dizziness when standing up.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine.
Yuvanci should not be taken during pregnancy, as it may harm the fetus. See section 2 "Do not take Yuvanci".
If you are a woman of childbearing age, your doctor will ask you to have a pregnancy test before starting Yuvanci and periodically (once a month) during treatment.
It is not known if Yuvanci passes into breast milk. Do not breast-feed during treatment with Yuvanci. Talk to your doctor if you are planning to breast-feed. See section 2 "Do not take Yuvanci"
Fertility
Yuvanci may cause a reduction in sperm count in men. Talk to your doctor if you are planning to have children.
Driving and using machines
Yuvanci may cause side effects such as headaches and low blood pressure (indicated in section 4), and the symptoms of pulmonary hypertension may also make you less fit to drive. Check carefully how you react to Yuvanci before driving or using machines.
Yuvanci contains lactose monohydrate and sodium
Follow exactly the administration instructions of this medicine given by your doctor. If you are unsure, ask your doctor or pharmacist.
The recommended dose of Yuvanci is one 10 mg/40 mg tablet once a day. In some situations, your doctor may decide to start with a lower dose of 10 mg/20 mg once a day, allowing your body to adapt to the new medicine. If you tolerate it, your doctor will then increase the dose to one 10 mg/40 mg tablet once a day.
Swallow the tablet whole with a glass of water. Do not chew or break the tablet. You can take Yuvanci with or without food. It is best to take the tablet at the same time each day.
If you take more Yuvanci than you should
Tell your doctor or pharmacist immediately. You may experience any of the side effects described in section 4.
If you forget to take Yuvanci
If you forget to take Yuvanci, take a dose as soon as you remember and then continue to take the tablets at the usual times. Do not take a double dose to make up for forgotten doses.
If you stop taking Yuvanci
Yuvanci is a treatment that you should continue to take to control PAH. Do not stop taking Yuvanci unless you have agreed this with your doctor.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
The adverse effects listed below have been observed with Yuvanci or have been previously reported with the active substances (macitentan or tadalafil) of Yuvanci and may also occur with Yuvanci.
If you experience any of the following adverse effects, stop using the medicine and seek immediate medical attention:
Other Adverse Effects
Very Common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Frequency Not Known(cannot be estimated)
Reporting Adverse Effects
If you experience any adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use Yuvanci after the expiration date stated on the carton and blister after "EXP". The expiration date is the last day of the month indicated.
Store in the original packaging to protect it from moisture.
This medicine does not require any special storage temperature.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.
Composition of Yuvanci
The active substances are macitentan and tadalafil.
Each 10 mg/20 mg film-coated tablet contains 10 mg of macitentan and 20 mg of tadalafil.
Each 10 mg/40 mg film-coated tablet contains 10 mg of macitentan and 40 mg of tadalafil.
The other ingredients are:
tablet core
hydroxypropylcellulose
hydroxypropylcellulose of low substitution (E463a)
magnesium stearate (E470b)
microcrystalline cellulose (E460i)
polysorbate 80 (E433)
povidone (E1201)
sodium glycolate starch (see section 2, Yuvanci contains sodium)
sodium lauryl sulfate
film coating
hypromellose
titanium dioxide (E171)
triacetin (E1518)
talc (E553b)
Yuvanci 10 mg/20 mg film-coated tablets also contain red iron oxide (E172) and yellow iron oxide (E172).
Appearance and Package Contents
Yuvanci 10 mg/20 mg film-coated tablets are pink, oblong, with the inscription "MT" on one side and "1020" on the other. Yuvanci 10 mg/20 mg is presented in 30 × 1 film-coated tablets in single-dose aluminum blisters with integrated desiccant.
Yuvanci 10 mg/40 mg film-coated tablets are white to almost white, oblong, with the inscription "MT" on one side and "1040" on the other. Yuvanci 10 mg/40 mg is presented in 30 × 1 film-coated tablets in single-dose aluminum blisters with integrated desiccant.
Marketing Authorization Holder
Janssen-Cilag International NV
Turnhoutseweg 30
B-2340 Beerse
Belgium
Manufacturer
Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse
Belgium
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
België/Belgique/Belgien Janssen-Cilag NV Tel/Tél: +32 14 64 94 11 janssen@jacbe.jnj.com | Lietuva UAB "JOHNSON & JOHNSON" Tel: +370 5 278 68 88 lt@its.jnj.com |
Luxembourg/Luxemburg Janssen-Cilag NV Tél/Tel: +32 14 64 94 11 janssen@jacbe.jnj.com | |
Ceská republika Janssen-Cilag s.r.o. Tel: +420 227 012 227 | Magyarország Janssen-Cilag Kft. Tel.: +36 1 884 2858 janssenhu@its.jnj.com |
Danmark Janssen-Cilag A/S Tlf.: +45 4594 8282 jacdk@its.jnj.com | Malta AM MANGION LTD Tel: +356 2397 6000 |
Deutschland Janssen-Cilag GmbH Tel: 0800 086 9247 / +49 2137 955 6955 jancil@its.jnj.com | Nederland Janssen-Cilag B.V. Tel: +31 76 711 1111 janssen@jacnl.jnj.com |
Eesti UAB "JOHNSON & JOHNSON" Eesti filiaal Tel: +372 617 7410 ee@its.jnj.com | Norge Janssen-Cilag AS Tlf: +47 24 12 65 00 jacno@its.jnj.com |
Ελλάδα Janssen-Cilag Φαρμακευτικ? Μονοπρóσωπη Α.Ε.Β.Ε. Tηλ: +30 210 80 90 000 | Österreich Janssen-Cilag Pharma GmbH Tel: +43 1 610 300 |
España Janssen-Cilag, S.A. Tel: +34 91 722 81 00 contacto@its.jnj.com | Polska Janssen-Cilag Polska Sp. z o.o. Tel.: +48 22 237 60 00 |
France Janssen-Cilag Tél: 0 800 25 50 75 / +33 1 55 00 40 03 medisource@its.jnj.com | Portugal Janssen-Cilag Farmacêutica, Lda. Tel: +351 214 368 600 |
Hrvatska Johnson & Johnson S.E. d.o.o. Tel: +385 1 6610 700 jjsafety@JNJCR.JNJ.com | România Johnson & Johnson România SRL Tel: +40 21 207 1800 |
Ireland Janssen Sciences Ireland UC Tel: 1 800 709 122 medinfo@its.jnj.com | Slovenija Johnson & Johnson d.o.o. Tel: +386 1 401 18 00 Janssen_safety_slo@its.jnj.com |
Ísland Janssen-Cilag AB c/o Vistor hf. Sími: +354 535 7000 janssen@vistor.is | Slovenská republika Johnson & Johnson, s.r.o. Tel: +421 232 408 400 |
Italia Janssen-Cilag SpA Tel: 800.688.777 / +39 02 2510 1 janssenita@its.jnj.com | Suomi/Finland Janssen-Cilag Oy Puh/Tel: +358 207 531 300 jacfi@its.jnj.com |
Sverige Janssen-Cilag AB Tfn: +46 8 626 50 00 jacse@its.jnj.com | |
Latvija UAB "JOHNSON & JOHNSON" filiale Latvija Tel: +371 678 93561 lv@its.jnj.com | United Kingdom (Northern Ireland) Janssen Sciences Ireland UC Tel: +44 1 494 567 444 medinfo@its.jnj.com |
Date of Last Revision of this Leaflet:
Detailed information on this medicine is available on the European Medicines Agency website: https://www.ema.europa.eu